Suppr超能文献

含1,3,4-恶二唑的化合物作为癌症治疗的治疗靶点

1,3,4-Oxadiazole Containing Compounds As Therapeutic Targets For Cancer Therapy.

作者信息

Ahsan Mohamed Jawed

机构信息

Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Jaipur, Rajasthan 302 039, India.

出版信息

Mini Rev Med Chem. 2022;22(1):164-197. doi: 10.2174/1389557521666210226145837.

Abstract

BACKGROUND

Cancer is the first or second leading cause of premature death in 134 of 183 countries in the world. 1,3,4-Oxadiazoles are five membered heterocyclic rings containing nitrogen (two atoms) and oxygen (one atom). They show better thermal stability, metabolic stability, aqueous solubility, and lower lipophilicity than the other isomeric oxadiazoles. They are important class of heterocycles present in many drug structures like Raltegravir, Furamizole Tidazosin, Nesapidil, Setileuton (MK-0633) and Zibotentan. The presence of this nucleus in therapeutics has made them an indispensable anchor for drug design and development. Several 1,3,4-oxadiazoles are prepared and reported as anticancer agents by numerous scientists worldwide.

OBJECTIVES

The present review discusses the anticancer potentials together with the molecular targets of 1,3,4-oxadiazoles reported since 2010. The Structure-Activity Relationship (SAR) and molecular docking simulation on different targets have also been discussed herein. Some of the important cancer targets have also been explored.

METHODS

The most potent 1,3,4-oxadiazoles reported in the literature were highlighted in the manuscript. The anticancer activity was reported in terms of Growth Percent (GP), percent growth inhibition (%GI), GI, IC, and LC; and TGI.

RESULTS

1,3,4-Oxadiazoles are important heterocyclic scaffolds with broad spectrum biological activities. They may be either mono substituted or disubstituted, and they may act as an indispensable anchor for drug design and discovery due to their thermal stability together with low lipophilicity. They exhibited anticancer potentials and showed the inhibitions of various cancer targets.

CONCLUSION

The discussion outlined herein will prove to be a helpful and vital tool for medicinal chemists investigating and working with 1,3,4-oxadiazoles and anticancer research programs.

摘要

背景

在世界183个国家中的134个国家,癌症是过早死亡的首要或第二大原因。1,3,4-恶二唑是含有氮(两个原子)和氧(一个原子)的五元杂环。与其他异构恶二唑相比,它们表现出更好的热稳定性、代谢稳定性、水溶性和更低的亲脂性。它们是许多药物结构(如拉替拉韦、呋拉米唑、替米沙坦、奈沙吡啶、西替利酮(MK-0633)和齐考诺肽)中存在的重要杂环类。该核在治疗学中的存在使其成为药物设计和开发中不可或缺的支撑。世界各地的众多科学家制备并报道了几种1,3,4-恶二唑作为抗癌剂。

目的

本综述讨论了自2010年以来报道的1,3,4-恶二唑的抗癌潜力及其分子靶点。本文还讨论了不同靶点的构效关系(SAR)和分子对接模拟。还探索了一些重要的癌症靶点。

方法

手稿中突出了文献报道的最有效的1,3,4-恶二唑。抗癌活性以生长百分比(GP)、生长抑制百分比(%GI)、GI、IC和LC以及TGI来报道。

结果

1,3,4-恶二唑是具有广谱生物活性的重要杂环支架。它们可以是单取代或双取代的,并且由于其热稳定性和低亲脂性,它们可能成为药物设计和发现中不可或缺的支撑。它们展现出抗癌潜力,并对各种癌症靶点具有抑制作用。

结论

本文所述的讨论将被证明是对研究1,3,4-恶二唑的药物化学家以及抗癌研究项目而言是一个有用且重要的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验